Point of Care Testing for Infectious Disease

Point of Care Testing for Infectious Disease Market Outlook

The global Point of Care Testing (POCT) for Infectious Disease market is projected to reach approximately USD 7 billion by 2032, growing at a compound annual growth rate (CAGR) of around 7.5% from 2022 to 2032. This growth can be attributed to the increasing prevalence of infectious diseases worldwide, the need for rapid diagnostic solutions, and advancements in technology that enhance the efficiency and accuracy of testing. Additionally, the growing demand for home-based testing solutions, spurred by the COVID-19 pandemic, has significantly contributed to the expansion of the POCT market. The rising awareness regarding timely diagnoses and treatment coupled with favorable government initiatives and policies are further propelling market growth.

Growth Factor of the Market

The growth of the Point of Care Testing for Infectious Disease market is significantly driven by the increasing global incidence of infectious diseases. The COVID-19 pandemic has amplified the necessity for efficient and swift testing methods, thereby accelerating the adoption of point of care technologies. Moreover, technological advancements such as the development of portable and user-friendly testing devices are transforming the diagnostic landscape, allowing for real-time results and immediate clinical decisions. Furthermore, the rise of telehealth and remote patient monitoring due to the pandemic has also facilitated the demand for POCT. The growing trend of home healthcare services and the shift towards decentralized testing are projected to be pivotal in the future growth of the market, as they provide greater accessibility and convenience for patients.

Key Highlights of the Market

• The global POCT for Infectious Disease market is expected to grow at a CAGR of 7.5% from 2022 to 2032.
• COVID-19 testing has significantly influenced the landscape of the market, driving innovation and adoption.
• Technological advancements are leading to the development of more accurate and efficient testing devices.
• The increasing prevalence of infectious diseases globally is a critical factor driving demand.
• Home care settings and remote testing are emerging as significant distribution channels for POCT.

By Product Type

Molecular POC Tests:

Molecular point of care tests represent a significant segment within the POCT for infectious disease market. These tests utilize techniques such as Polymerase Chain Reaction (PCR) to detect genetic material from pathogens. The advantage of molecular POC tests lies in their ability to provide rapid, highly sensitive results, often within a matter of hours. This is particularly crucial in the diagnosis of diseases like HIV, tuberculosis, and COVID-19, where time-sensitive diagnosis and treatment are imperative. The growing emphasis on early detection and management of infectious diseases is driving the demand for molecular testing, making it a vital component of the market.

Immunoassays:

Immunoassays are another critical product type in the POCT for infectious disease landscape. These tests detect the presence of antibodies or antigens related to infectious agents, providing a reliable means of diagnosis. The allure of immunoassays lies in their simplicity and ease of use, which allows them to be utilized in various settings, including clinics and home care environments. Their ability to deliver results quickly contributes to effective disease management, particularly during outbreaks of diseases such as influenza and COVID-19. As healthcare providers increasingly seek rapid and user-friendly diagnostic options, the immunoassay segment is expected to continue growing robustly in the forthcoming years.

Microbiology Testing:

The microbiology testing segment within the POCT market plays a crucial role in identifying infectious pathogens through culture and sensitivity testing. This type of testing is essential for diagnosing bacterial infections and determining antibiotic resistance, which is increasingly critical in the face of rising antibiotic-resistant strains. Microbiology tests allow for the identification of causative agents and the selection of appropriate therapeutic strategies promptly. As the global burden of infectious diseases rises, alongside increasing awareness about antimicrobial resistance, microbiology testing is expected to gain traction, further driving the growth of the POCT market.

Hematology Testing:

Hematology testing is a vital component of the point of care testing market, particularly in the diagnosis of various infectious diseases that affect blood parameters. This type of testing involves the analysis of blood samples to detect anomalies such as anemia, infection, or blood disorders. Rapid hematology tests enable healthcare providers to make informed decisions regarding patient management swiftly. The convenience of portable hematology analyzers allows for testing in various settings, including emergency rooms and clinics. As the need for immediate diagnostic information increases, the hematology testing segment is likely to expand, contributing to the overall growth of the POCT market.

Urinalysis Testing:

Urinalysis testing is another significant segment in the POCT for infectious disease market, offering insights into the presence of infections in the urinary tract. These tests analyze urine samples for signs of infection, such as the presence of leukocytes or nitrates. Point of care urinalysis tests are particularly valuable in settings like primary care clinics and emergency departments, allowing for quick diagnosis and treatment of urinary tract infections. As the global awareness of urinary tract infections increases, and as patients seek more accessible testing solutions, the demand for urinalysis tests is anticipated to rise, bolstering the growth of this segment within the market.

By Application

Hospitals:

Hospitals are among the primary applications for point of care testing in infectious diseases. The ability to obtain rapid diagnostic results is essential in acute care settings where timely treatment can significantly impact patient outcomes. POCT allows healthcare providers to make swift decisions regarding patient management, reducing the time patients spend waiting for results. Moreover, hospitals are increasingly adopting point of care testing to enhance workflow efficiency and optimize resource utilization in emergency departments, intensive care units, and surgical settings. The growing focus on patient-centered care within hospital environments is expected to further drive the adoption of POCT technologies.

Clinics:

Clinics also play a vital role in the application of point of care testing for infectious diseases. These healthcare facilities often cater to patients seeking immediate medical attention for various conditions, including infections. The implementation of POCT in clinics enhances the ability to diagnose and manage infectious diseases on-site, thereby reducing the need for laboratory referrals and follow-up visits. With the increasing emphasis on patient convenience and streamlined care, clinics are increasingly integrating point of care testing into their practice. This trend is driven by the need for efficient patient management and the demand for accessible diagnostic solutions in outpatient settings.

Home Care:

The home care setting is becoming increasingly important in the point of care testing market, especially following the COVID-19 pandemic. The trend towards at-home testing solutions allows patients to conduct tests in the comfort of their own homes, ensuring greater convenience and accessibility. Home care POCT empowers individuals to monitor their health and detect infections early, leading to timely treatment and reduced hospital visits. As technology advances and more user-friendly testing devices become available, the adoption of home care testing is expected to surge, significantly impacting the overall growth of the market.

Assisted Living Facilities:

Assisted living facilities represent another significant application area for point of care testing in infectious diseases. Residents in these facilities are often elderly or immunocompromised, making them more susceptible to infections. POCT enables healthcare providers in assisted living facilities to conduct timely tests for infections, ensuring prompt diagnosis and treatment. The ability to perform testing on-site reduces the need for transportation to external laboratories, enhancing the overall quality of care for residents. As the demand for personalized healthcare services in assisted living continues to grow, the integration of POCT is expected to expand, thereby influencing market dynamics positively.

Research Institutes:

Research institutes are crucial in the application of point of care testing for infectious diseases, particularly in the context of developing new diagnostic methods and conducting epidemiological studies. These institutions leverage POCT technologies to gather data on infectious disease prevalence and outbreaks, ultimately contributing to public health initiatives. The increasing focus on research and development in the healthcare sector is likely to promote the integration of innovative point of care testing solutions. As research institutions collaborate with industry players to advance diagnostic technologies, the role of research institutes in the POCT market is expected to become increasingly prominent.

By Distribution Channel

Hospitals:

Hospitals form a significant distribution channel for point of care testing solutions. The need for rapid diagnostic tools in hospital environments, particularly in emergency departments and critical care units, drives the demand for POCT products. Hospitals are increasingly investing in point of care technologies to streamline patient care and enhance diagnostic capabilities. The integration of POCT into hospital workflows not only improves patient outcomes by enabling timely treatment but also increases overall operational efficiency. As hospitals continue to prioritize rapid diagnostics, the distribution of POCT solutions is expected to grow substantially.

Pharmacies:

Pharmacies are becoming an increasingly important distribution channel for point of care testing. With the growing demand for accessible healthcare services, many pharmacies are now offering POCT for infectious diseases, enabling patients to receive quick tests without a physician's appointment. This convenience is appealing to consumers, as it allows for rapid diagnosis and immediate access to treatment options. Additionally, pharmacies can play a role in educating patients on the importance of early detection and management of infectious diseases. As the healthcare landscape evolves, the role of pharmacies in the distribution of POCT solutions is anticipated to expand, facilitating greater access to testing.

Online Retailers:

The emergence of online retailers as a distribution channel for point of care testing products marks a significant shift in the market. Online platforms provide consumers with the ability to purchase testing kits conveniently from home, further driving the trend towards decentralized healthcare solutions. This distribution channel is especially relevant given the rise in demand for at-home testing solutions, catalyzed by the COVID-19 pandemic. The accessibility and ease of ordering POCT products online contribute to a broader consumer base, allowing individuals to take charge of their health proactively. As e-commerce continues to grow, it is expected to become a prominent channel for distributing point of care testing solutions.

Diagnostic Centers:

Diagnostic centers serve as a critical distribution channel for point of care testing in infectious diseases. These facilities specialize in conducting tests and providing diagnostic information to healthcare providers, making them a vital link in the healthcare continuum. The integration of POCT into diagnostic centers allows for rapid testing, with results often available within hours, which is crucial in accurately diagnosing and managing infectious diseases. As the demand for timely and reliable diagnostics increases, the role of diagnostic centers in the distribution of POCT products is projected to expand, enhancing their importance in the healthcare ecosystem.

Others:

Other distribution channels for point of care testing solutions include various healthcare settings, such as urgent care clinics and mobile health units. These venues cater to specific patient populations and often require rapid diagnostic capabilities to manage infectious diseases effectively. The flexibility and adaptability of POCT solutions make them suitable for diverse healthcare environments. As the emphasis on patient-centered care continues to grow, these alternative distribution channels are likely to become increasingly relevant. Ultimately, the evolution of distribution channels will contribute to the overall growth and accessibility of point of care testing for infectious diseases.

By Infectious Disease Type

COVID-19:

The COVID-19 pandemic has dramatically transformed the landscape of point of care testing for infectious diseases. Rapid testing for COVID-19 became a necessity for controlling the spread of the virus, leading to a surge in demand for point of care solutions that deliver quick results. Various types of POCT devices, including antigen and molecular tests, have been deployed widely in hospitals, clinics, and at home. As the situation evolves, the focus on developing and refining COVID-19 testing technologies continues, ensuring that healthcare providers can efficiently diagnose and manage patients. The sustained interest in POCT for COVID-19 is expected to have a lasting impact on the market, driving further innovation.

Influenza:

Influenza is another significant infectious disease type influencing the point of care testing market. Rapid diagnostic tests for influenza allow for timely treatment, reducing complications and improving patient outcomes. The POCT for influenza encompasses various methodologies, including rapid antigen tests and molecular assays, which have been widely adopted in healthcare settings. The seasonality of influenza outbreaks contributes to periodic spikes in demand for these testing solutions, making them a critical component of seasonal healthcare management. As awareness of the impact of influenza increases, the point of care testing market for this disease type is projected to continue its growth trajectory.

HIV/AIDS:

HIV/AIDS testing remains a crucial component of the point of care testing for infectious diseases segment, offering rapid results that are vital for early diagnosis and intervention. POCT for HIV/AIDS encompasses a range of tests, including antibody and viral load testing, allowing healthcare providers to identify infected individuals quickly. The growing global awareness and education surrounding HIV/AIDS, along with government initiatives aimed at increasing testing rates, are driving the adoption of point of care testing for this disease. As efforts to combat HIV/AIDS continue, the demand for rapid and accessible testing solutions is expected to remain strong, contributing to market growth.

Tuberculosis:

Tuberculosis (TB) presents another critical area for point of care testing, as timely diagnosis is essential for controlling its spread. POCT for TB includes nucleic acid amplification tests and rapid culture systems, which facilitate quick identification of TB infections. The WHO's emphasis on early detection and treatment of TB aligns with the growing adoption of point of care testing solutions globally. As regions continue to combat TB, especially in low- and middle-income countries, the market for POCT in this disease type is poised for growth, driven by the need for effective diagnostic and management strategies.

Hepatitis:

Hepatitis is also a significant infectious disease category within the point of care testing market. Rapid tests for hepatitis allow for the swift identification of infections, enabling timely interventions and reducing the risk of transmission. Various POCT methodologies, including serological tests and molecular diagnostics, are crucial for managing hepatitis effectively. The increase in awareness surrounding hepatitis prevention and treatment, coupled with expanding healthcare access in developing regions, is expected to drive the demand for POCT solutions in this area. As global initiatives work towards eliminating hepatitis, the point of care testing market for this disease type will likely see continued growth.

By Region

The North American region is expected to dominate the point of care testing for infectious disease market during the forecast period, accounting for approximately 40% of the global market share by 2032. The growth in this region can be attributed to the presence of advanced healthcare infrastructures, increased healthcare expenditure, and a rising incidence of infectious diseases. Furthermore, the regulatory framework in North America supports innovation and rapid market entry for new testing technologies, fostering a competitive landscape conducive to growth. The increased emphasis on patient-centric care and the demand for quick diagnostics in clinical settings are also propelling the market forward.

In Europe, the point of care testing for infectious disease market is projected to grow at a CAGR of 6.8% from 2022 to 2032, reaching a significant share by the end of the forecast period. The region is characterized by a robust healthcare system, increasing prevalence of infectious diseases, and a growing focus on decentralized healthcare solutions. The European market is also witnessing heightened investments in research and development related to POCT technologies. Additionally, the increasing awareness among patients and healthcare providers regarding the benefits of rapid diagnostics is driving substantial growth in this region as well.

Opportunities

The point of care testing for infectious disease market is rife with opportunities as technological advancements continue to shape the landscape of diagnostics. The ongoing development of innovative testing devices that offer higher sensitivity, specificity, and ease of use is poised to drive significant growth. These advancements present an opportunity for manufacturers to differentiate their products and cater to the evolving needs of healthcare providers and patients. Additionally, the increasing emphasis on telehealth and remote monitoring due to the ongoing pandemic creates avenues for integrating point of care solutions into broader healthcare models, enabling patients to receive timely and efficient care regardless of their location. This shift towards decentralized healthcare presents a promising growth trajectory for the market as it aligns with the changing dynamics in patient management.

Moreover, the rise in global health initiatives aimed at combating infectious diseases presents a significant opportunity for the point of care testing market. Governments and organizations are increasingly investing in programs that promote early detection and treatment of infectious diseases, thereby expanding access to diagnostic tools. Collaborative efforts between public health organizations and private companies to develop cost-effective testing solutions for resource-limited settings can further enhance market growth. The growing awareness of the importance of timely diagnostics in managing infectious diseases, particularly in developing regions, offers a favorable environment for innovation and expansion in the POCT market.

Threats

Despite the promising outlook for the point of care testing for infectious disease market, several threats could hinder its growth. One primary concern is the potential for regulatory challenges and stringent approval processes for new testing devices. The need for high-quality, reliable tests necessitates rigorous validation and compliance with regulatory standards, which can delay market entry for new products. Furthermore, as the market becomes more saturated with various testing solutions, competition will likely intensify, leading to potential price wars that could jeopardize profitability for manufacturers. The evolving nature of infectious diseases, including the emergence of new pathogens and mutations, poses additional challenges, as it may necessitate continuous innovation and adaptation of testing methodologies, increasing research and development costs.

Another significant threat is the potential for misinterpretation of test results, especially with rapid tests that provide results in a short time frame. False positives or negatives can lead to inappropriate treatment decisions, which can have serious implications for patient safety. The lack of proper education and training for healthcare providers in interpreting point of care test results may exacerbate this situation, underscoring the need for comprehensive training programs. Additionally, the ongoing challenge of healthcare disparities in access to diagnostic testing may hinder the overall effectiveness of point of care solutions in addressing infectious diseases, particularly in underserved populations.

Competitor Outlook

• Abbott Laboratories
• Roche Diagnostics
• Siemens Healthineers
• BD (Becton, Dickinson and Company)
• Thermo Fisher Scientific
• bioMérieux
• Quidel Corporation
• Ortho Clinical Diagnostics
• Hologic
• Danaher Corporation
• PerkinElmer
• Diagnostics Instruments, Inc.
• NantHealth
• GenMark Diagnostics

The competitive landscape of the point of care testing for infectious disease market is characterized by a mix of established players and emerging companies striving to innovate and capture market share. Major companies such as Abbott Laboratories and Roche Diagnostics are leading the way, particularly with their advanced technologies and extensive product portfolios. These companies have invested heavily in research and development to streamline testing processes and enhance the accuracy and reliability of their products. The focus on strategic partnerships, mergers, and acquisitions is also evident in the market, as companies look to broaden their reach and improve their capabilities in response to the growing demand for rapid diagnostics.

Siemens Healthineers and BD (Becton, Dickinson and Company) are also notable competitors, bringing their expertise in medical technology to the POCT market. Siemens Healthineers has a strong foothold in point of care molecular diagnostics, enabling rapid testing solutions for various infectious diseases. Meanwhile, BD has made significant strides in developing innovative testing devices that cater to the evolving needs of healthcare providers. The competition among these key players fosters an environment of continuous improvement and innovation, ensuring that the market remains dynamic and responsive to emerging challenges in infectious disease management.

Emerging companies such as GenMark Diagnostics and Quidel Corporation are also making significant contributions to the competitive landscape. These companies focus on developing cutting-edge testing technologies that leverage molecular diagnostics and rapid antigen testing, respectively. Their agility and commitment to innovation allow them to respond quickly to market demands and evolving healthcare needs. As the landscape continues to evolve, collaboration among industry stakeholders, including public health organizations and academic institutions, will play a crucial role in driving advancements in point of care testing. The competitive outlook remains promising, with numerous opportunities for growth and development as the market addresses the pressing challenges posed by infectious diseases.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Hologic
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 NantHealth
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 PerkinElmer
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Roche Diagnostics
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 bioMérieux
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Quidel Corporation
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Abbott Laboratories
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Danaher Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 GenMark Diagnostics
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Siemens Healthineers
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Thermo Fisher Scientific
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Ortho Clinical Diagnostics
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Diagnostics Instruments, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 BD (Becton, Dickinson and Company)
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Point of Care Testing for Infectious Disease Market, By Application
    • 6.1.1 Hospitals
    • 6.1.2 Clinics
    • 6.1.3 Home Care
    • 6.1.4 Assisted Living Facilities
    • 6.1.5 Research Institutes
  • 6.2 Point of Care Testing for Infectious Disease Market, By Product Type
    • 6.2.1 Molecular POC Tests
    • 6.2.2 Immunoassays
    • 6.2.3 Microbiology Testing
    • 6.2.4 Hematology Testing
    • 6.2.5 Urinalysis Testing
  • 6.3 Point of Care Testing for Infectious Disease Market, By Distribution Channel
    • 6.3.1 Hospitals
    • 6.3.2 Pharmacies
    • 6.3.3 Online Retailers
    • 6.3.4 Diagnostic Centers
    • 6.3.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Point of Care Testing for Infectious Disease Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Point of Care Testing for Infectious Disease market is categorized based on

By Product Type

• Molecular POC Tests
• Immunoassays
• Microbiology Testing
• Hematology Testing
• Urinalysis Testing

By Application

• Hospitals
• Clinics
• Home Care
• Assisted Living Facilities
• Research Institutes

By Distribution Channel

• Hospitals
• Pharmacies
• Online Retailers
• Diagnostic Centers
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Abbott Laboratories
• Roche Diagnostics
• Siemens Healthineers
• BD (Becton, Dickinson and Company)
• Thermo Fisher Scientific
• bioMérieux
• Quidel Corporation
• Ortho Clinical Diagnostics
• Hologic
• Danaher Corporation
• PerkinElmer
• Diagnostics Instruments, Inc.
• NantHealth
• GenMark Diagnostics